6 January, 2021 – Mardi Gomberg-Maitland, MD, MSc, Director of the Pulmonary Hypertension Program at the George Washington University Heart and Vascular Institute in Washington, DC USA, has been elected as a Director on the Board of the International Society for Heart and Lung Transplantation.
“I’m super excited and honored to join the Board of Directors,” said Dr. Gomberg-Maitland. “I especially want to thank Dr. Ray Benza and Dr. Myung Park for luring me to ISHLT and its then-fledgling PH Council. The Society has allowed me to grow as a leader and my hope is that I can help it continue to advance care at the highest level.”
ISHLT is committed to improving the care of patients with advanced heart and lung disease through research, education, and advocacy, and is the world’s largest multi-disciplinary organization of its kind. ISHLT will welcome Dr. Gomberg-Maitland as Director at the 41st Annual ISHLT Annual Meeting & Scientific Sessions in April 2021.
Dr. Gomberg-Maitland is an internationally recognized leader in the field of pulmonary hypertension. She spent 12 years as Director of the Pulmonary Hypertension Program at the University of Chicago before her current role. A highly respected leader in the development and testing of new pulmonary hypertension medications, Dr. Gomberg-Maitland has established a comprehensive pulmonary hypertension program at the George Washington University Hospital/George Washington University of Medicine & Health Sciences.
Dr. Gomberg-Maitland has served in a variety of roles for ISHLT, including the Program Committee, as Associate Chair for the Standards and Guidelines Committee, Chair for the PH Core Academy, Chair and Vice Chair for the Pulmonary Hypertension Council, and as speaker at the Annual Meeting and for the PH and CTEPH Academies.
###
The International Society for Heart and Lung Transplantation is a not-for-profit, multidisciplinary professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies. With more than 3,800 members in more than 45 countries, ISHLT is the world’s largest organization dedicated to the research, education and advocacy of end-stage heart and lung disease. ISHLT members represent more than 15 different professional disciplines. For more information, visit